Apros Therapeutics, Inc.

Apros Therapeutics, Inc. is a biotechnology company founded in 2016 and headquartered in the United States. The company's focus lies in the development of tissue-targeted small molecule innate immune agonists to enhance tumor immunogenicity, with a specific emphasis on immunotherapeutics for cancer and infectious disease. Apros Therapeutics aims to transform "cold" tumors into "hot" ones through innovative chemistry approaches that enable precise targeting of the agonist to specific tumors and tissues while minimizing systemic distribution. As of now, the company has not disclosed its latest investment details or the identity of the investors. With its unique approach and focus on addressing critical unmet medical needs, Apros Therapeutics presents an intriguing prospect in the biotechnology and life sciences industries, with potential for significant impact in the field of immunotherapy.